A STUDY OF CAROTID INTIMA-MEDIA THICKNESS and RETINAL ARTERY CHANGES IN PATIENTS WITH NON ALCOHOLIC FATTY LIVER DISEASE.

Non-Alcoholic Fatty Liver Disease (NAFLD) is one of the most common liver diseases reported all over the world and the disease spectrum ranges from simplesteatosis to non-alcoholic steato-hepatitis to cirrhosis . NAFLD has strong association with metabolic syndrome. The carotid intima-media thickness (CIMT) is considered to be a non-invasive marker for atherosclerosis andthe thickness is directly proportional to the presence of atherosclerosis in the coronary vessels and the severity of cardiovascular disease. Aims And Objectives:1. To measure the thickness of Carotid Intima Media (CIMT) in patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and compare it with Controls, to establish the strong association of NAFLD with increased CIMT and to prove that NAFLD an independent risk factor for cardiovascular morbidity.. 2. To look for any associated retinal vascular changes in NAFLD Materials And Methods: This study will be conducted between June 2016 to November 2016, among Patients with non alcoholic fatty liver who are admitted in General Medicine Department Of Government Rajaji Hospital, Madurai and equal number of age matched controls. Results: We found the strong association between NAFLD and carotid intima media thickness as p value is 0.001. Mean carotid intima media thickness in NAFLD is 0.9284mm compared to 0.6695 in control group. We also found the strong association between NAFLD and retinal vascular changes as p value is 0.004. 12 patients have retinal changes in NAFLD group compared to 2 patients in control group. Conclusion: Non-Alcoholic Fatty Liver Disease (NAFLD) is one of the most common liver diseases reported all over the world.Carotid Intima Media Thickness (CIMT) is a useful tool for detection of sub-clinical atherosclerosis. In our study, we found that, there is strong association between, NAFLD and Carotid intima media thickness, Retinal artery changes. So all patients with NAFLD should be investigated with carotid Doppler, and they all should treated with statins and other cardioprotective drugs to prevent cardiovascular complication. They all should get treatment for obesity and with insulin sensitizers to prevent the progression of NAFLD. This simple and non-invasive practice will help in early diagnosis ofcardiovascular disease, especially in overt cases.